MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Emotional valence and arousal ratings from rewarding and fearful stimuli are not influenced by levodopa in Parkinson’s disease

T. Serranova, T. Sieger, P. Dušek, E. Ruzicka, R. Jech (Prague, Czech Republic)

Meeting: 2016 International Congress

Abstract Number: 359

Keywords: Deep brain stimulation (DBS), Dopamine

Session Information

Date: Monday, June 20, 2016

Session Title: Parkinson's disease: Non-motor symptoms

Session Time: 12:30pm-2:00pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To analyze the effects of levodopa on affective ratings of emotional valence and arousal to rewarding, fearful and neutral stimuli in PD patients and matched controls.

Background: Dopamine and deep brain stimulation (DBS) of the subthalamic nucleus (STN) have been shown to affect different aspects of emotional and motivational processes in Parkinson’s disease (PD). STN DBS increased activity of the aversive motivational system: the valence of fearful stimuli was experienced as more negative with DBS switched on (1). However, it is not known if STN DBS mimics the effects of dopaminergic medication on subjective emotional experience.

Methods: We examined 15 PD patients (all men, aged 58.4 (SD 6) years, disease duration 15(SD 6)) and 20 male controls using the same affective task that was previously used to examine the effects of STN DBS. Patients were tested in the OFF- condition (3-days washout of dopamine agonists and an overnight withdrawal of levodopa) and the ON- condition (on levodopa, best motor improvement) in a balanced order. Subjects rated a series of 84 pictures depicting rewarding, fearful and neutral stimuli according to emotional valence (from unpleasant to pleasant) and arousal (from calm to excited) on separate visual scales ranging from 1 to 9. The effect of levodopa on motor symptoms was assessed using the Unified PD Rating Scale part III (UPDRS III).

Results: The UPDRS III scores decreased from 39.9(SD 10) in the OFF condition to 13.3(SD6) in the ON condition (P<.001). We did not find any significant differences in affective valence and arousal ratings (category specific and overall ratings) between ON- vs. OFF- condition or between the patients and the control group.

Conclusions: In contrast to the previously demonstrated impact of STN DBS on valence ratings to fearful stimuli, in this study we failed to demonstrate the effects of dopamine on subjective ratings of affective valence and arousal to rewarding and fearful stimuli. These results suggest that the effects of STN DBS on emotional processing may be caused by a different mechanism than an increase of dopaminergic input. Supported by GACR 16-13323S and PRVOUK P26/LF1/4. 1. Serranová T. et al. (2011) Subthalamic nucleus stimulation affects incentive salience attribution in Parkinson’s disease. Mov Disord.

To cite this abstract in AMA style:

T. Serranova, T. Sieger, P. Dušek, E. Ruzicka, R. Jech. Emotional valence and arousal ratings from rewarding and fearful stimuli are not influenced by levodopa in Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/emotional-valence-and-arousal-ratings-from-rewarding-and-fearful-stimuli-are-not-influenced-by-levodopa-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/emotional-valence-and-arousal-ratings-from-rewarding-and-fearful-stimuli-are-not-influenced-by-levodopa-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley